Related Experiment Video

Updated: Jul 4, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin

Korey K Hood1, Aika K Schneider-Utaka1, Zachariah W Reed2

  • 1Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine, Stanford Diabetes Research Center, Stanford, CA, USA.

Diabetes Research and Clinical Practice
|January 26, 2024
PubMed

Insights

The t:slim X2 insulin pump with Control-IQ technology (CIQ) significantly improved patient-reported outcomes in young children with type 1 diabetes, reducing hypoglycemia concerns and parenting stress.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Patient-Reported Outcomes

Background:

  • Type 1 diabetes management in young children presents unique challenges.
  • Continuous glucose monitoring and automated insulin delivery systems aim to improve glycemic control and quality of life.

Purpose of the Study:

  • To evaluate patient-reported outcomes (PROs) in young children (2 to <6 years) with type 1 diabetes using the t:slim X2 insulin pump with Control-IQ technology (CIQ).

Main Methods:

  • A randomized controlled trial compared CIQ to standard care (SC) for 13 weeks in 102 children.
  • PRO questionnaires assessed hypoglycemia concerns, quality of life, parenting stress, and sleep at baseline, 13, and 26 weeks.
  • User-experience interviews were conducted with 28 families at 26 weeks.

Main Results:

  • All 5 PRO surveys favored the CIQ group over SC at 26 weeks (p < 0.05).
  • Families reported optimized glycemic control, particularly nighttime control, and a substantial reduction in management burden.
  • 26/28 families desired continued use of CIQ.

Conclusions:

  • CIQ use in young children with type 1 diabetes offers significant benefits beyond glycemic control.
  • Improved PROs include reduced hypoglycemia concerns, decreased parenting stress, enhanced quality of life, and better sleep.
  • CIQ demonstrates a positive impact on family well-being in managing type 1 diabetes.
Abstract

Keywords:
Automated insulin deliveryFear of hypoglycemiaPsychosocialSleepType 1 diabetesYoung children

More Related Videos

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.6K
Iterative Development of an Innovative Smartphone-Based Dietary Assessment Tool: Traqq04:54

Iterative Development of an Innovative Smartphone-Based Dietary Assessment Tool: Traqq

Published on: March 19, 2021

4.6K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
197
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
209